Table 3 Association of insulin resistance index with new onset hypertension phenotype

TyG index

0.835 (0.663–1.052)

0.12

1.355 (1.121–1.637)

0.002

1.056 (0.799–1.396)

0.70

TG/HDL-C

0.975 (0.915–1.040)

0.44

1.060 (1.025–1.096)

0.001

1.012 (0.942–1.087)

0.75

METS-IR

0.634 (0.326–1.233)

0.18

3.006 (1.747–5.171)

< 0.001

1.624 (0.716–3.683)

0.24

ZJU index

0.995 (0.985–1.005)

0.30

1.005 (1.000–1.010)

0.04

1.005 (0.997–1.013)

0.23

Incidence of stage I hypertension

TyG index

0.826 (0.653–1.046)

0.11

1.376 (1.123–1.687)

0.002

0.828 (0.575–1.193)

0.31

TG/HDL-C

0.975 (0.913–1.041)

0.44

1.082 (1.039–1.127)

< 0.001

0.964 (0.873–1.065)

0.46

METS-IR

0.619 (0.313–1.221)

0.16

3.455 (1.921–6.214)

< 0.001

1.196 (0.425–3.366)

0.73

ZJU index

0.995 (0.984–1.005)

0.31

1.005 (0.999–1.011)

0.09

0.995 (0.980–1.009)

0.47

Incidence of stage II hypertension

TyG index

1.643 (0.892–3.027)

0.11

1.265 (0.825–1.939)

0.28

2.821 (1.244–6.395)

0.01

TG/HDL-C

1.074 (0.931–1.240)

0.32

1.049 (0.974–1.130)

0.20

1.161 (0.963–1.398)

0.11

METS-IR

4.216 (0.689–25.80)

0.11

2.179 (0.622–7.628)

0.22

6.940 (0.617–78.10)

0.11

ZJU index

1.013 (1.003–1.023)

0.009

1.011 (1.001–1.021)

0.03

1.010 (0.982–1.038)

0.49